(Reuters) – A European regulatory panel has recommended the approval of Lynparza, a blockbuster cancer treatment developed by AstraZeneca Plc and Merck & Co Inc, to treat two separate forms of cancer.
The European Medicines Agency recommended Lynparza for patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, AstraZeneca added.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Saumyadeb Chakrabarty)
